Photo taken from Vivek Subbiah/Twitter
Aug 30, 2023, 17:46
Vivek Subbiah: Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.
In a post by Vivek Subbiah, the Chief Early-Phase Drug Development at Sarah Cannon Research Institute, on LinkedIn, it says:
“At 35 months’ follow-up, the survival benefit of cemiplimab for patients with advanced non-small-cell lung cancer was at least as pronounced as at 1 year, affirming its use as first-line monotherapy for this population. Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.”
For the article click here.
Source: Vivek Subbiah/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 2, 2024, 15:28
Dec 2, 2024, 15:25
Dec 2, 2024, 13:53